CAM
PACB icon

Cresset Asset Management’s Pacific Biosciences PACB Stock Holding History

Cresset Asset Management’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-80,000
Closed -$1.06M – 1938
2023
Q2 		$1.06M Buy
+80,000
New +$972K ﹤0.01% 915

Other funds holding PACB

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Cresset Asset Management's PACB Position: Q1 2026 in Review

Cresset Asset Management increased its Pacific Biosciences (PACB) stake by 2.4% in Q1 2026, buying an estimated $989 and bringing the position to 23,508 shares worth $31K. The position accounts for ﹤0.01% of the portfolio, ranked #1591.

Cresset Asset Management first reported a position in PACB in Q3 2020 and has held it in 20 quarters since. The position peaked at $2.34M in Q2 2021. 229 funds tracked by Wall St. Rank hold PACB as of Q1 2026.

  • Cresset Asset Management held 23,508 shares of Pacific Biosciences worth $31K as of Q1 2026.
  • Cresset Asset Management bought 553 Pacific Biosciences shares in Q1 2026, an estimated $989.
  • Pacific Biosciences made up ﹤0.01% of Cresset Asset Management's portfolio in Q1 2026, its #1591 holding.
  • Cresset Asset Management first reported a position in Pacific Biosciences in Q3 2020 and has held it in 20 quarters since.
  • Cresset Asset Management's Pacific Biosciences position peaked at $2.34M in Q2 2021.
  • 229 funds tracked by Wall St. Rank held Pacific Biosciences as of Q1 2026.

Based on Cresset Asset Management's 13F filing for Q1 2026, filed 15 May 2026.